BioSpace News Archive

Ansys is teaming with Microsoft to deploy public cloud high-performance computing (HPC) and digital twin solutions that will significantly advance the state of the art in engineering simulation across several key industries

Company Will Report Data from Phase 2a Sensorineural Hearing Loss (SNHL) Study in Late Q1 2021 First Patient Dosed in Phase 1b Study of Age-Related Hearing Loss; Additional Phase 1b Study for Severe SNHL Patients to Start This Quarter

Castle Biosciences to Present Data at the American Society of Dermatopathology (ASDP) 57 th Virtual Annual Meeting Presentations to highlight two of Castle’s skin cancer gene expression profile tests

Under Amulet’s ownership, Synteract drove organic growth, integrated several strategic acquisitions, more than doubled EBITDA and expanded its global delivery footprint

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-01, the company’s investigational gene therapy for the treatment of Fabry disease. AVR-RD-01, an ex-vivo, lentiviral gene therapy, consists of the patient’s own hematopoietic stem ce

Indivior PLC (LON: INDV) today announced that financial results for the third quarter and nine months period ended September 30, 2020 , including the press release and investor supplement, are now available on the Group’s website at www.indivior.com .

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its third quarter 2020 financial results on Monday, November 9, 2020, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced that it has recruited Don Cilla, PharmD, MBA, to serve as the Company’s new Chief Development Officer (CDO), effective November 1, 2020. In this role, Dr. Cilla will oversee the strategy and execution of the preclinical and clinical programs for Appili

Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will file its third quarter 2020 financial results on Thursday, November 5, 2020 after market close and will host a conference call that same day at 4:30 PM ET, during which management will discuss the

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced the commencement of COMET-1, a Phase 2b clinical trial of AR-15512 ophthalmic solution for the treatment of patients with dry eye disease.